In this emerging in the form of cooperation, biological medicine industry further extended to the biological agents in the form of outsourcing cooperation contract development and manufacturing organization (CDMO) mode, the CDMO from preclinical studies and clinical trials to commercial production stage and the enterprise research and development, procurement, production, such as depth of the whole supply chain system docking, provide enterprises with innovative technology research and development and large-scale production services, in the higher value-added technology output instead of the pure output capacity.
This report contains market size and forecasts of Biologics Contract Development and Manufacturing Organization(CDMO) in Global, including the following market information:
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Biologics Contract Development and Manufacturing Organization(CDMO) market was valued at 11640 million in 2021 and is projected to reach US$ 23370 million by 2028, at a CAGR of 10.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biologics Contract Development Services Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biologics Contract Development and Manufacturing Organization(CDMO) include Lonza, Hansen, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, Samsung BioLogics, AGC Biologics, Catalent and Wuxi Biologics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biologics Contract Development and Manufacturing Organization(CDMO) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Segment Percentages, by Type, 2021 (%)
Biologics Contract Development Services
Biologics Contract Manufacturing Services
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Segment Percentages, by Application, 2021 (%)
Big Pharma
Small Pharma
Generic Pharma
Other
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biologics Contract Development and Manufacturing Organization(CDMO) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Biologics Contract Development and Manufacturing Organization(CDMO) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lonza
Hansen
Boehringer Ingelheim BioXcellence
Thermo Fisher Scientific
Samsung BioLogics
AGC Biologics
Catalent
Wuxi Biologics